Research
Blood test may reveal which lymphoma patients will respond to immunotherapy
The Brief
- Cornell engineers and Dana-Farber oncologists report that RNA circulating in blood plasma carries a signature of a lymphoma tumor's surroundings.
- The plasma RNA signature tracked with whether patients were still in remission a year later.
- The finding is presented as a possible way to identify which lymphoma patients will respond to immunotherapy.
Why it matters
A simple blood test that predicts immunotherapy response could help clinicians choose treatments more precisely and avoid ineffective therapy, though it remains an early research finding.
Who’s affected
- oncologists and lymphoma patients
- researchers working on liquid biopsy and cancer biomarkers
- #lymphoma
- #immunotherapy
- #liquid biopsy
- #plasma rna
- #cancer biomarkers
Cornell engineers and Dana-Farber oncologists found that RNA floating in the plasma carries a signature of a lymphoma tumor's surroundings, one that tracked with whether patients were still in remission a year later.